Fiessinger J N, Paul J F, Alhenc-Gelas M, Veyssier C, Martin J B, Aiach M
Service de Pathologie vasculaire, Centre Claude-Bernard de recherche sur les maladies vasculaires périphériques.
Presse Med. 1992 Jan 18;21(2):65-8.
Thirty-one consecutive patients with deep vein thrombosis were treated with Fraxiparine, a low molecular weight heparin, and fluindione, an oral anticoagulant prescribed at an early stage. Despite the weight/biological effectiveness ratio, the dose of Fraxiparine had to be adjusted in 46 percent of the patients to remain within the therapeutic range selected (0.5 to 1 antiXa/ml units). The early administration of fluindione reduced the duration of heparin therapy to 5.75 days. Using a prescription guide on days 2 and 4 might improve the safety of the fluindione induction.
31例连续的深静脉血栓形成患者接受了低分子量肝素法安明和早期使用的口服抗凝剂氟茚二酮治疗。尽管考虑了体重/生物效应比，但仍有46%的患者需要调整法安明的剂量，以使其保持在选定的治疗范围内（0.5至1抗Xa/ml单位）。早期使用氟茚二酮可将肝素治疗时间缩短至5.75天。在第2天和第4天使用处方指南可能会提高氟茚二酮诱导的安全性。
